Theralase Technologies (CVE:TLT) Stock Price Down 2.6%

Theralase Technologies Inc. (CVE:TLT)’s stock price was down 2.6% on Thursday . The company traded as low as C$0.19 and last traded at C$0.19. Approximately 102,000 shares were traded during trading, a decline of 15% from the average daily volume of 120,588 shares. The stock had previously closed at C$0.20.

Theralase Technologies Price Performance

The company has a quick ratio of 3.40, a current ratio of 1.21 and a debt-to-equity ratio of 20.58. The stock has a market cap of C$44.92 million, a P/E ratio of -9.25 and a beta of 1.39. The business’s 50-day simple moving average is C$0.18 and its two-hundred day simple moving average is C$0.18.

Theralase Technologies (CVE:TLT) last issued its earnings results on Thursday, May 30th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.18 million for the quarter. Sell-side analysts expect that Theralase Technologies Inc. will post -0.05 EPS for the current year.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.